MarginsXMarginsX
Home › Markets › Health Care › RANI

Rani Therapeutics Holdings Inc. (RANI)

RANI trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.5403
+2.66% on the day
Market cap
$75.4M
Micro cap
Revenue · 2025
$1.6M
+58.9% on 2024
Net income · 2025
-$29.7M
-1817.1% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1856725/000119312526126417/0001193125-26-126417-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerRANI on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2021
SEC CIK0001856725
SEC industry codePharmaceutical Preparations
Incorporated inCALIFORNIA

Financials · 2025

LineValue
Revenue$1.6M
Net income-$29.7M
Operating income-$38.3M
Net margin-1817.1%
Operating margin-2346.0%
Revenue growth+58.9%
Cash$18.6M
Total assets$58.6M
P/E (computed)Net income was not positive
P/S (computed)46.1×

Warning signs

Cash runway
1.9 months
$3.6M cash at September 30, 2026
Share count, 1 year
+14.8%
2025-10-31 to 2026-10-31
Going-concern doubt
No
10-Q filed November 9, 2026
Insider net buying, 12 months
-$14.4M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-09
Cash and burn$3.6M cash; operating cash flow -$5.7M a quarter.Report 2026-09-30
Shares outstanding139,460,921 (2026-10-31); 121,511,580 a year earlier.Cover page 2026-10-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 2 424B5 takedowns, 1 at the marketLatest 2026-05-27
Exchange deficiency notices, 12 months2 (8-K item 3.01)8-K 2026-11-12
AuditorCBIZ CPAs P.C., San Francisco, California, United States; changed auditors 1 time in 24 months8-K 4.01 2025-04-09
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $1.3M, sold $15.7M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$1.7M-$7.7M-$7.8M$3.6MNo debt tags$6.6M10-Q 2026-11-09
Q2 2026
2026-06-30
$1.7M-$7.4M-$9.0M$4.9MNo debt tags$4.9M10-Q 2026-08-13
Q1 2026
2026-03-31
$1.7M-$7.0M-$6.5M$9.6MNo debt tags$3.2M10-Q 2026-05-15
Q4 2025
2025-12-31
$1.5M-$10.3M$294K$18.6M$0$1.6M10-K 2026-03-26
Q3 2025
2025-09-30
$0-$5.4M-$5.1M$4.1M$13.8M$1.2M10-Q 2026-11-09
Q2 2025
2025-06-30
$0-$6.7M-$5.8M$10.2M$17.5M$1.2M10-Q 2026-08-13
Q1 2025
2025-03-31
$172K-$7.3M-$8.1M$10.1M$21.3M$1.2M10-Q 2026-05-15
Q4 2024
2024-12-31
$1.0M-$8.9M-$8.7M$3.8M$25.0M$1.0M10-K 2026-03-26

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-05-27
Latest annual report10-K2026-03-26
Latest quarterly / interim10-Q2026-11-09
Latest current report8-K2026-11-12
Latest proxy
DEFA 14A
DEFA14A2026-04-16

Source: SEC EDGAR submissions feed, 384 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-3.8%
1 month-28.2%
3 months-34.1%
Year to date-61.0%
1 year-72.7%
From 52-week high-72.9%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
KALAKALA BIO Inc.$3.83-8.02%$74.1M
TLSATiziana Life Sciences Ltd. Common Shares$0.5762+1.11%$73.3M
CPIXCumberland Pharmaceuticals Inc.$5.21-11.39%$78.1M
VTVTvTv Therapeutics Inc.$17.69-10.16%$71.0M
COYACoya Therapeutics Inc.$3.00-4.15%$70.4M
CRBPCorbus Pharmaceuticals Holdings Inc.$3.38-0.44%$69.5M
MNOVMedicinova Inc$1.34-3.94%$68.7M
PLYXPolaryx Therapeutics Inc.$1.67-6.99%$83.2M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier